Skip to contents

Robert Patrick Giugliano, MD, MSc
Associate Professor of Medicine, Harvard Medical School

Brigham and Women's Hospital
Department of Medicine
Cardiovascular
75 Francis Street
Boston, MA 02115


Edit Profile


Research Narrative:

Dr. Robert Giugliano's areas of research interests include novel antithrombotic and fibrinolytic agents for acute coronary syndromes (ACS), lipid-lowering therapies, and the assessment of outcomes in patients with ACS. He has authored over 100 articles, 25 editorials/book chapters, and given over 150 lectures nationally and internationally.

Dr. Giugliano has served as the lead investigator and physician-in-charge of six multicenter phase-II or III trials (TIMI 15A, TIMI 15B, INTEGRITI-TIMI 20, ADVANCE MI-TIMI 29, ANTHEM-TIMI 32, EARLY-ACS TIMI 39).  In addition, he has worked closely with Dr. Elliott Antman and Dr. Christopher Cannon coordinating another six international trials, and continues to serve as the local investigator  as a participating hospital for four additional studies.  He is a co-investigator of five international thrombolytic studies working with Drs. Antman (TIMI 14, InTIME-II, and InTIME-IIb) and Cannon (TIMI 10B, ASSENT I) and one international trial with Dr Cannon in lipid-lowering therapies (IMPROVE-IT).

Outside of TIMI, he continues to collaborate with independent research groups (Massachusetts General Hospital, Montreal Heart Institute) studying clinical practice guidelines and risk stratification in unstable angina.

www.timi.org


Education:
Harvard School of Public Health, 1997, MSc
Harvard Medical School, 1989, MD

Publications (Pulled from Harvard Catalyst Profiles):

1. Franken M, Giugliano RP, Goodman SG, Baracioli LM, Godoy LC, Furtado RHM, Lima FG, Nicolau JC. Performance of acute coronary syndrome approaches in Brazil. A report from the BRACE (Brazilian Registry in Acute Coronary syndromEs). Eur Heart J Qual Care Clin Outcomes. 2019 Aug 10.

2. Furtado RHM, Giugliano RP, Dalcoquio TF, Arantes FBB, Barbosa CJDG, Genestreti PRR, Franci A, Menezes FR, Nakashima CAK, Scanavini Filho MA, Ferrari AG, Salsoso R, Baracioli LM, Nicolau JC. Increased bodyweight and inadequate response to aspirin in individuals with coronary artery disease. J Thromb Thrombolysis. 2019 Aug; 48(2):217-224.

3. Park S, Bergmark BA, Shi M, Lanz HJ, Chung N, Ruff CT, Antman EM, Braunwald E, Giugliano RP. Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial. Hypertension. 2019 Sep; 74(3):597-605.

4. Bach RG, Cannon CP, Giugliano RP, White JA, Lokhnygina Y, Bohula EA, Califf RM, Braunwald E, Blazing MA. Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2019 Jul 17.

5. Qamar A, Antman EM, Ruff CT, Nordio F, Murphy SA, Grip LT, Greenberger NJ, Yin OQP, Choi Y, Lanz HJ, Mercuri MF, Braunwald E, Giugliano RP. Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease. J Am Coll Cardiol. 2019 Jul 16; 74(2):179-189.

6. Murphy SA, Pedersen TR, Gaciong ZA, Ceska R, Ezhov MV, Connolly DL, Jukema JW, Toth K, Tikkanen MJ, Im K, Wiviott SD, Kurtz CE, Honarpour N, Giugliano RP, Keech AC, Sever PS, Sabatine MS. Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial. JAMA Cardiol. 2019 Jul 01; 4(7):613-619.

7. Charytan DM, Sabatine MS, Pedersen TR, Im K, Park JG, Pineda AL, Wasserman SM, Deedwania P, Olsson AG, Sever PS, Keech AC, Giugliano RP. Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial. J Am Coll Cardiol. 2019 Jun 18; 73(23):2961-2970.

8. Sabatine MS, Giugliano RP, Leiter LA. Correctly understanding the diabetes data in FOURIER. Diabetes Obes Metab. 2019 Jun 10.

9. Qamar A, Giugliano RP, Sabatine MS. Interindividual and Intraindividual Responses to PCSK9 Inhibition-Reply. JAMA Cardiol. 2019 Jun 01; 4(6):600-601.

10. Beik N, Reddy P, Sylvester KW, Connell NT, Giugliano RP, Piazza G, Connors JM. Andexanet Alfa (Andexxa) Formulary Review. Crit Pathw Cardiol. 2019 Jun; 18(2):66-71.